Affordable Access

Myo-inositol has no beneficial effect on premenstrual dysphoric disorder.

Authors
Type
Published Article
Journal
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
Publication Date
Volume
3
Issue
3
Pages
147–149
Identifiers
PMID: 12478879
Source
Medline
License
Unknown

Abstract

Inositol, a simple isomer of glucose, which serves as a precursor in the phosphatidyl-inositol (PI) second messenger cycle, was shown to be effective in double-blind, placebo-controlled studies of depression, panic and obsessive compulsive disorders as well as in bulimia. The following study was designed to investigate whether inositol has beneficial effects in another disorder shown to be responsive to SSRIs: premenstrual dysphoric disorder (PMDD). Eleven female patients with PMDD diagnosed according to DSM-IV participated in a cross-over, double-blind, placebo-controlled trial. The active drug was myo-inositol, 12 g daily, whereas placebo was d-glucose administered at the same dose. Each drug was given during the luteal phase only (14 days prior to menses). For each patient treatment alternated between these two drugs for six menstrual cycles. No beneficial effect was demonstrated for inositol over placebo.

Statistics

Seen <100 times